Annexin Pharmaceuticals (Q4 review): Phase II study away, with positive initial results - Redeye
Redeye comments on Annexin’s Q4 report and recent events and see good initial progress in the phase II study. We adjust our financial assumptions and FX a bit, resulting in a slightly revised valuation.
ANNONS
Redeye comments on Annexin’s Q4 report and recent events and see good initial progress in the phase II study. We adjust our financial assumptions and FX a bit, resulting in a slightly revised valuation.
